e-Therapeutics plc announces that it has started a randomised double-blind controlled phase IIb trial of ETS6103 in major depressive disorder. The trial is evaluating ETS6103 as a second-line treatment for patients who have not responded adequately to first-line therapy with an SSRI (selective serotonin reuptake inhibitor). It is being conducted by a group of primary care centres with a history of involvement in depression studies in the Glasgow area of Scotland.
31 October, 2013
The theme of this month's Editors Choice is "Animal Models"
29 October, 2013
Ablynx today announced that its partner Boehringer Ingelheim has dosed the first healthy volunteers in a Phase I clinical trial as part of the evaluation of a Nanobody® for the treatment of Alzheimer’s disease. The start of the Phase I study triggers a milestone payment of €5 million to Ablynx.
29 October, 2013
A living cell is built with barriers to keep things out – and researchers are constantly trying to find ways to smuggle molecules in. ?Professor Giovanni Maglia (Biochemistry, Molecular and Structural Biology, KU Leuven) and his team have engineered a biological nanopore that acts as a selective revolving door through a cell’s lipid membrane. The nanopore could potentially be used in gene therapy and targeted drug delivery.
24 October, 2013
There has been tremendous interest from delegates, poster presenters and exhibitors, following the announcement by ELRIG (the European Laboratory Robotics Interest Group) who will be hosting a unique, 2 day conference entitled ‘Advances in Recombinant Protein Technologies – towards redesigned synthetic systems’. The free to attend conference will be held at Astra Zeneca R&D’s Alderly Park Site on 19th and 20th November and is strictly limited to 220 attendees.
21 October, 2013
CPhI announces exhibitors latest product news and Awards finalists ahead of showCPhI Pharma Award Finalists.Best Innovation in Process DevelopmentAPI Corporation: A novel and practical synthesis of highly functionalized pharmaceuticals through C-H activation;Bachem: Pioneering breakthrough in the chemical synthesis of Interferon ß-1a;Codexis: Enzymes for Green and Scalable Biocatalytic OxidationsBest Innovation in FormulationBitop: Ectoin - a new natural ingredient with proven efficacy;Camurus: FluidCrystal Injection depotEmulTech: Microfluidic platform for controlled development;Best Innovation in PackagingE-Pharma Trento: E-PHARMA TRENTO SpA;Doctor Pack India: MAGIC CAP;Neutroplast: Vaginal applicator
18 October, 2013
Award celebrates achievements of a dynamic business with strong future growth prospects
17 October, 2013
Major Euros 7 billion infrastructure investment now underway, while protein science companies continue to expandA new report published today in conjunction withe Nordic Life Science Days by Stockholm-Uppsala Life Science, Stockholm Science City and Uppsala BIO shows that despite taking a hit from the widely reported Astra Zeneca closures over the last years, the region maintained its position as one of the leading international life science clusters (data from 2011).
16 October, 2013
The UK’s Chief Medical Officer Dame Sally Davies is to be the keynote speaker at a flagship conference focused on the global threat to public health posed by antibiotic resistance.
15 October, 2013
The latest issue of Drug Discovery Today is packed full of industry focused research articles, new developments in drug discovery, and expert comment and opinion.
14 October, 2013
Hundreds of researchers from North America, Europe, Australia and Asia have joined together in a consortium to identify the genetic basis of the five most common forms of cancer - breast, prostate, lung, ovarian and colorectal. The group, called the OncoArray Consortium, developed a new customized genotyping tool - the OncoArray - manufactured by the U.S. genomics firm Illumina, Inc.
10 October, 2013
Optibrium, a developer of software for drug discovery, today announced that it will join the HeCaToS (Hepatic and Cardiac Toxicity Systems) project, a major European project with the objective to efficiently investigate the health impact of compounds on the heart and liver. The EU is providing twelve million Euros for the project, which is co-ordinated by Maastricht UMC+
09 October, 2013
Korea is to develop its first national centre of excellence for the development and validation of alternatives to animal testing. Humane Society International, which works with governments and scientists in Korea and globally to replace animals in research, says this will dramatically improve Korea's ability to implement cutting-edge science.
08 October, 2013
What does a porcupine, a handful of newly sharpened pencils and a festival loo seat have in common? They all come with a warning: 'Don't Sit On It'!
05 October, 2013
The whisky and salmon industries in Scotland are about to embark on an innovative new partnership which will convert waste from whisky production into feed for salmon and fish farming.
04 October, 2013
Over 40% of exhibitors at Lab Innovations 2013, which returns to Birmingham’s NEC on 6 & 7 November, are using the show to launch new technologies and services into the UK. Here is a brief first overview of just some of the products debuting at the show.
03 October, 2013
Cancer researchers are not shy of using nanotechnology. Their work is making promising headway into developing safer and more effective treatments.
02 October, 2013
The BioIndustry Association (BIA) and UK Trade and Investment (UKTI) today announce the nine leading UK companies that will showcase UK expertise in synthetic biology (synbio) at SynBioBeta SF 2013, a key global synbio start-up conference taking place in California in November.
01 October, 2013